Stabile Marzia, Lacitignola Luca, Samarelli Rossella, Fiorentino Marco, Crovace Antonio, Staffieri Francesco
Dipartimento Dell'Emergenza e Trapianti di Organi, Sez. Cliniche Veterinarie e P.A., Università Degli Studi di Bari, Strada Provinciale Per Casamassima Km.3, 70010 Valenzano, Italy.
Dipartimento di Medicina Veterinaria, Sez. Patologia Aviare, Università Degli Studi di Bari, Strada Provinciale Per Casamassima Km.3, 70010 Valenzano, Italy.
Res Vet Sci. 2022 Dec 10;151:27-35. doi: 10.1016/j.rvsc.2022.06.030. Epub 2022 Jul 10.
The aim of the study was to evaluate the clinical efficacy of 30 days treatment of undenatured type II collagen(UC-II®), compared to cimicoxib and to their combination, in osteoarthritic dogs. Client-owned dogs were enrolled in a clinical, randomized, controlled and prospective study. Posture, lameness, pain, range of motion and x-ray of affected joint(s) were evaluated and scored based on severity (CLINICAL score). The Liverpool Osteoarthritis in Dogs survey was used to score the owner evaluation of dog's mobility (LOAD score and MOBILITY score). Osteoarthritis (OA) stage was defined through the Canine Osteoarthritis Staging tool (COAST). After diagnosis (T0), all patients were randomly assigned to different treatment groups: C group = cimicoxib 2 mg/kg/day orally OS, F group = UC-II® 1 tablet per day OS; C + F group = cimicoxib-UC-II® at the same previous dosages; CTR group = dogs who didn't received any treatment. All treatments were administered for 30 days. Seventy-six dogs completed the study. LOAD score was recorded significant lower after treatment for each group, with a reduction in percentage of 29.5% for C, 31.4% for F, 21.1% for C + F. LOAD score was lower in C(P = 0.04), F(P = 0.001) and C + F(P = 0.009) group at T30 than CTR group. MOBILITY and CLINICAL scores were significantly lower in all groups at T30, when compared to T0. MOBILITY score was lower than CTR in C(P = 0.02) and F(P = 0.01); CLINICAL score was lower in C + F(P = 0.016). The present findings prove that the treatment with UC-II®, cimicoxib and their combination provide significant reduction in clinical signs associated with OA.
本研究旨在评估未变性II型胶原蛋白（UC-II®）、西咪考昔及其联合用药对患骨关节炎犬进行30天治疗的临床疗效。客户拥有的犬只被纳入一项临床、随机、对照和前瞻性研究。根据严重程度对姿势、跛行、疼痛、活动范围和患关节的X光进行评估并评分（临床评分）。使用利物浦犬骨关节炎调查问卷对主人对犬只活动能力的评估进行评分（LOAD评分和活动能力评分）。通过犬骨关节炎分期工具（COAST）定义骨关节炎（OA）阶段。诊断后（T0），所有患者被随机分配到不同治疗组：C组=口服西咪考昔2mg/kg/天；F组=每天口服1片UC-II®；C+F组=西咪考昔-UC-II®，剂量同前；CTR组=未接受任何治疗的犬只。所有治疗均持续30天。76只犬完成了研究。每组治疗后记录的LOAD评分均显著降低，C组降低百分比为29.5%，F组为31.4%，C+F组为21.1%。在T30时，C组（P=0.04）、F组（P=0.001）和C+F组（P=0.009）的LOAD评分低于CTR组。与T0相比，所有组在T30时的活动能力和临床评分均显著降低。C组（P=0.）和F组（P=0.01）的活动能力评分低于CTR组；C+F组的临床评分更低（P=0.016）。目前的研究结果证明，使用UC-II®、西咪考昔及其联合用药治疗可显著减轻与OA相关的临床症状。
